NCT02477748终止3 期
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Alcobra Ltd.
- 入组人数
- 283
- 试验地点
- 36
- 主要终点
- 18-item total ADHD symptom score of the Conners Adult ADHD Rating Scale:O-SV (with the investigator as observer) with adult ADHD prompts (CAARS investigator).
研究概览
简要总结
This study is a multi-center, randomized, double-blind, placebo-controlled, phase 3 study of MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.
The study will be comprised of Screening, Washout (if required), Treatment (total of 10 weeks) and Follow-up periods. Approximately 750 patients will be enrolled and undergo initial eligibility assessments.
详细描述
- A 10-week randomized, multi-center, double-blind, placebo-controlled, phase 3 study of MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.
- The study will be comprised of Screening, Washout (if required), Treatment (total of 10 weeks) and Follow-up periods. Approximately 750 patients will be enrolled and undergo initial eligibility assessments.
- Subjects requiring a washout will undergo a Washout period where ADHD medication is discontinued (21 days for atomoxetine, 14 days for other ADHD medications). These subjects will have an Interim Visit (off drug) on or about Day -10 (Day -10 to Day -3) for CAARS-Inv assessment at the end of the Washout period.
- Subjects will be randomly assigned to placebo/MDX for a total treatment duration of up to ten weeks.
There will be a one week Follow-up period after the last dose of study treatment or early termination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is a man or a non-pregnant, non-lactating woman 18 to 55 years of age, inclusive, at the Screening visit.
- •Subject has a diagnosis of ADHD based on criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) as assessed by the Adult ADHD Clinician Diagnostic Scale, (ACDS Version 1.2) modified for DSM-IV and DSM5 diagnoses; a diagnosis of ADHD not otherwise specified is unacceptable.
- •Male and Female subjects of childbearing potential must agree to use an effective contraceptive throughout the study
- •Subject is able to attend the clinic regularly and reliably.
- •Subject is able to swallow tablets and capsules.
- •Subject is able to understand, read, write, and speak the local language fluently to complete the study-related materials.
- •Subject is able to understand and sign an informed consent form to participate in the study.
- •Exclusion criteria
- •Subject has any current major psychiatric condition (e.g., schizophrenia, bipolar or personality disorder) or autism spectrum disorder.
- •Subject has any clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation.
- •Subject has used an investigational medication/treatment or was enrolled in another clinical trial in the 30 days before the Screening visit.
- •Subject has used any medication or food supplement that the investigator or the medical monitor consider unacceptable during the 14-day period before the Baseline visit.
- •Subject's alcohol and caffeine intake will be assessed.
- •Subject has current suicidality, defined as active ideation, intent or plan, or any significant lifetime suicidal behavior (actual attempt, aborted attempt, interrupted attempt, or act or preparation towards imminently making a suicide attempt). Subjects exhibiting history (within previous 12 months) of non-suicidal self-injurious behavior will be excluded.
- •Subject has taken any prescription or non-prescription medication for ADHD during the 14 days (or 21 days for atomoxetine) before the Baseline visit. Subjects will not be allowed to take any other medications for ADHD besides the study medication (when prescribed) after the washout period and for the duration of the study, up to and including the safety Follow-up visit. (Other ADHD medications should NOT be prescribed to subjects before completion of the Follow-up visit or Early Termination Visit).
- •Subject is significantly visually impaired to an extent that is not able to be corrected by prescription glasses or contact lenses.
- •Subject is closely related to the sponsor, investigator, or study staff. Eligibility of subjects with any relationship to the sponsor, investigator, or study staff will be discussed with the medical monitor before study entry, and the medical monitor will decide on the eligibility of these cases.
- •Subject has previously been enrolled in an MDX clinical trial.
- •Subject lives in the same household as another subject in this clinical trial or in another on-going trial with MDX. Subject lives in the same household as someone who has previously participated in a trial with MDX.
- •Subject has any condition that, in the principal investigator's opinion, would place the subject at risk or influence the conduct of the study or interpretation of results, including (but not limited to) abnormally low intellectual capacity as judged by the investigator.
- •Subject cannot fully comprehend the implications of the protocol, cannot comply with its requirements, or is incapable of following the study schedule for any reason.
- •Subject is pregnant, lactating, or using an inadequate contraceptive method. Complete entry criteria will be reviewed and evaluated individually by a protocol trained delegate.
排除标准
- 未提供
研究组 & 干预措施
MDX
Active Comparator
Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
干预措施: MDX (Drug)
Placebo
Placebo Comparator
Inert tablets
干预措施: Placebo (Drug)
结局指标
主要结局
18-item total ADHD symptom score of the Conners Adult ADHD Rating Scale:O-SV (with the investigator as observer) with adult ADHD prompts (CAARS investigator).
时间窗: 10 weeks
The scale will be analyzed by change from Baseline to Week 10.
次要结局
- Questionnaires of Clinical Global Severity of Illness (CGI-S) and Clinical Global Improvement (CGI-I).(10 weeks)
- Safety as assessed by adverse events (AEs)(10 weeks)
- Safety as assessed by Columbia Suicide Severity Rating Scale (C-SSRS)(10 weeks)
- Safety as assessed by neurological evaluation(10 weeks)
- Safety as assessed by physical examinations(10 weeks)
- Safety as assessed by discontinuations due to AEs(10 weeks)
- Safety as assessed by heart rate measurements(10 weeks)
- Safety as assessed by Electrocardiogram (ECG) test(10 weeks)
- Adult ADHD Self Report Scale (ASRS-Self) v1.1 Symptom Checklist - expanded version(10 weeks)
- Test of Variables of Attention (TOVA)(10 weeks)
- Safety as assessed by respiratory rate measurements(10 weeks)
- Safety as assessed by supine blood pressure(10 weeks)
- Safety as assessed by body temperature measurements(10 weeks)
- Safety as assessed by laboratory tests; blood and urine(10 weeks)
研究者
研究点 (36)
Loading locations...
相似试验
已完成
3 期
Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure ProphylaxisCOVID-19NCT05722691Promomed, LLC800
尚未招募
3 期
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)NCT05715840CSPC ZhongQi Pharmaceutical Technology Co., Ltd.368
进行中（未招募）
3 期
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsMyopiaNCT06209320Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.777
已完成
3 期
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With NarcolepsyNarcolepsyCataplexyExcessive Daytime SleepinessNCT05059223Axsome Therapeutics, Inc.90
已完成
3 期
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaFibromyalgiaNCT04508621Tonix Pharmaceuticals, Inc.514